

¹⁸F-FDG PET/CT imaging of multiple intrahepatic Epstein-Barr virus-associated smooth muscle tumors in a pediatric patient after heart transplantation

Abstract

Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is an exceedingly rare neoplastic disease with a predisposition in immune-compromised individuals, especially in patients with prior transplantation, human immunodeficiency virus infection, or congenital immunodeficiency. Here, we present imaging findings of EBV-SMT in multiphase contrast-enhanced computed tomography (CT) and fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/CT in a two-and-a-half-year-old boy with prior heart transplantation.

Hell J Nucl Med 2022; 25(3): 320-322

Epub ahead of print: 14 December 2022

Published online: 30 December 2022




Figure 1. A two-and-a-half-year-old boy was admitted to the hospital for persisting cough and sputum over 10 days. He had a prior heart transplantation due to dilated cardiomyopathy at one year old. The laboratory test at his administration revealed a high amplification of Epstein-Barr virus (EBV) DNA (2100 copies/mL, reference <500 copies/mL), elevated serum lactate dehydrogenase level (340U/L, reference <250U/L), and otherwise unremarkable findings. Physical examination identified hepatic enlargement with several nodules. Subsequent multiphase contrast-enhanced computed tomography (CT) scan demonstrated numerous intrahepatic hypodense lesions with faint-to-mild homogenous (black arrows) and rim-like (white arrows) arterial enhancement and wash-out in portal-venous and delayed phases (A-H). Whole-body fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/CT was performed to evaluate the involved extent of the disease, which showed innumerable hypermetabolic foci within the liver with maximum standardized uptake value (SUVmax) up to 8.2 (I-O), and bilateral lung inflammation with mild ¹⁸F-FDG uptake (images not showed). Differential diagnoses of infection, primary and metastatic liver malignancies, and post-transplant lymphoproliferative disorder (PTLD) were made.




Figure 2. The patient underwent a CT-guided fine-needle biopsy at the hepatic S2 mass. The histological study revealed a mixture of spindle-shaped to ovoid cells on hematoxylin-eosin (HE) staining (A), which were positive for Ki-67 (B) and smooth muscle actin (SMA) (C) on immunohistochemical staining, and EBV in situ hybridization (D), confirming the diagnosis of EBV-associated smooth muscle tumor (EBV-SMT).

Epstein-Barr virus has been identified as a transforming virus linked to many diseases, including lymphoma, nasopharyngeal carcinoma, gastric carcinoma, and PTLD, but rarely EBV-SMT [1-4]. Epstein-Barr virus-SMT is mainly diagnosed in patients with prior transplantation or infection with human immunodeficiency virus and is usually multifocal, involving sites that are uncommon for conventional SMT [5-8]. It lacks characteristic clinical and imaging manifestations and thus requires histopathology for confirmation [8]. Histologically, it appears as a spectrum from well-differentiated spindle-shaped smooth muscle cells to ovoid cells with incomplete smooth muscle cell differentiation and can be diagnosed using the following criteria: 1) positive for at least one smooth muscle marker including smooth muscle actin (SMA), caldesmon and desmin, and 2) positive for EBV by in situ hybridization [5, 9, 10].

Due to the extensive disease spread within the liver, the patient was a non-surgical candidate. He received only conservative management, including a reduction in immunosuppression, antiviral therapy using Acyclovir, and oral sirolimus as a mammalian target of rapamycin (mTOR) inhibitor. Unfortunately, he developed disease progression 3 months later, as shown by the follow-up abdominal MRI scan, and thus is currently under palliative care.

The authors declare that they have no conflicts of interest.

Funding: This work was supported by the fund from the National Natural Science Foundation of China (81971645), Guangdong Provincial People's Hospital (KY0120211130), and Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application (2022B1212010011).

Bibliography

1. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. *N Engl J Med* 2004; 350: 1328-37.
2. Grulich AE, van Leeuwen MT, Falster MO et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet* 2007; 370: 59-67.
3. El-Sharkawy A, Al Zaidan L, Malki A. Epstein-Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis. *Front Oncol* 2018; 8: 265.
4. Hiramata T, Tikkanen J, Pal P et al. Epstein-Barr virus-associated smooth muscle tumors after lung transplantation. *Transpl Infect Dis* 2019; 21: e13068.
5. Deyrup AT, Lee VK, Hill CE et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. *Am J Surg Pathol* 2006; 30: 75-82.
6. Szklarz MT, Tessi C, Ruiz J et al. Epstein-Barr virus associated smooth muscle tumour as an unusual cause of ureteric graft obstruction in a child. *Pediatr Transplant* 2021; 25: e14109.
7. Bourhis A, Roussel-Robert V, Viard JP et al. A case of Epstein-Barr virus-associated smooth muscle tumor of the posterior interosseous nerve mimicking schwannoma. *Neuropathology* 2022; 42: 52-7.
8. Garg I, Baladron Zanetti MJ, Yasir S et al. PET/CT in an 8-Year-Old Girl With Epstein-Barr Virus-Associated Smooth Muscle Tumor. *Clin Nucl Med* 2017; 42: 770-2.
9. Jossen J, Chu J, Hotchkiss H et al. Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. *Pediatr Transplant* 2015; 19: 235-43.
10. Dekate J, Chetty R. Epstein-Barr Virus-Associated Smooth Muscle Tumor. *Arch Pathol Lab Med* 2016; 140: 718-22.

Hui Yuan^{1*} MD, PhD, Baozhen Zeng^{2*} MD, PhD, Li He^{1*} MD, Xiaoyue Tan¹ MD, Lei Jiang^{1,3} MD, PhD

1. PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, 2. Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, 3. Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.

*Equally contributed to this work.

Corresponding author: Lei Jiang MD, PhD, PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510080, China. Email: leijiang1031@163.com
